Expert Interview
Discussing CD20xCD3 Bispecifics in DLBCL, with a focus on glofitamab & Epcoritamab
Ticker(s): ABBV, RHHBYInstitution: University of Miami
- Professor of Medicine and the Director of Lymphoma Program and Chief of Lymphoma Section at Sylvester Comprehensive Cancer Center at University of Miami.
- Research focuses on the pathogenesis of lymphoma, identification of molecular prognostic markers and elucidation of their role in determination of response to therapy, development of new lymphoma therapies.
- PI or Co-PI on numerous trials; his studies focus on diffuse large cell lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, primary CNS lymphoma, lymphomas of the eye and other lymphoma subtypes.
How many DLBCL patients do you treat?
Added By: wilson_adminHow has your experience been with glofitamab or Epcoritamab
Added By: wilson_adminHow does this class affect your treatment algorithm
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
